/NUVB
NUVB Stock - Nuvation Bio Inc.
Healthcare|BiotechnologyNYSE
$9.44+4.95%
+$0.45 (+4.95%) • Dec 19
78
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).92
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.57
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+20.8%upside
Target: $11.40
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NUVB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.35 – $9.53
TARGET (TP)$11.40
STOP LOSS$8.68
RISK/REWARD1:2.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.59
52W High$9.53
52W Low$1.54
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $7.87M | N/A | N/A | N/A | N/A |
| Gross Profit | $795,000 | N/A | N/A | N/A | $-103,000 |
| Gross Margin | 10.1% | N/A | N/A | N/A | N/A |
| Operating Income | $-592,627,000 | $-99,822,000 | $-119,734,000 | $-93,318,000 | $-43,551,000 |
| Net Income | $-567,939,000 | $-75,802,000 | $-104,199,000 | $-86,848,000 | $-41,659,000 |
| Net Margin | -7213.8% | N/A | N/A | N/A | N/A |
| EPS | $-2.11 | $-0.35 | $-0.48 | $-0.44 | $-0.19 |
Company Overview
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
78%
Hold / Neutral
2
22%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
7 Bullish2 Neutral/Bearish
Price Targets
$8
Average Target
↓ 18.6% Downside
Now
$2
Low
$8
Average
$14
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 24th 2025 | Truist | Initiation | Buy | - |
| November 19th 2025 | B. Riley Securities | Initiation | Buy | $12 |
| September 30th 2025 | Jefferies | Initiation | Buy | $10 |
| April 23rd 2025 | Citizens JMP | Initiation | Mkt Outperform | $6 |
| March 27th 2024 | Jefferies | Upgrade | Buy | $10← $1.4 |
| March 26th 2024 | BTIG Research | Upgrade | Buy | $5 |
| January 6th 2023 | Jefferies | Downgrade | Hold | $2← $5 |
| August 2nd 2022 | BMO Capital Markets | Downgrade | Market Perform | $2.5← $8 |
| August 2nd 2022 | BTIG Research | Downgrade | Neutral | - |
| May 4th 2022 | H.C. Wainwright | Initiation | Buy | $14 |
Earnings History & Surprises
NUVBBeat Rate
44%
Last 18 quarters
Avg Surprise
-3.0%
EPS vs Estimate
Beats / Misses
8/5
5 met exactly
Latest EPS
$-0.16
Q4 2025
EPS Surprise History
Q1 24
+40.0%
$-0.06vs$-0.10
Q2 24
+12.5%
$-0.07vs$-0.08
Q3 24
-150.0%
$-0.15vs$-0.06
Q4 24
-15.4%
$-0.15vs$-0.13
Q1 25
-7.1%
$-0.15vs$-0.14
Q2 25
0.0%
$-0.16vs$-0.16
Q3 25
0.0%
$-0.17vs$-0.17
Q4 25
+5.9%
$-0.16vs$-0.17
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $-0.11 | — | — | — |
Q4 2025 | Nov 3, 2025 | $-0.17 | $-0.16 | +5.9% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.17 | $-0.17 | 0.0% | = MET |
Q2 2025 | May 7, 2025 | $-0.16 | $-0.16 | 0.0% | = MET |
Q1 2025 | Mar 6, 2025 | $-0.14 | $-0.15 | -7.1% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.13 | $-0.15 | -15.4% | ✗ MISS |
Q3 2024 | Aug 5, 2024 | $-0.06 | $-0.15 | -150.0% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.08 | $-0.07 | +12.5% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $-0.10 | $-0.06 | +40.0% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-0.10 | $-0.09 | +10.0% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.11 | $-0.09 | +18.2% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.09 | $-0.10 | -11.1% | ✗ MISS |
Q1 2023 | Mar 15, 2023 | $-0.10 | $-0.10 | 0.0% | = MET |
Q4 2022 | Nov 3, 2022 | $-0.14 | $-0.12 | +14.3% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.13 | $-0.16 | -23.1% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.15 | $-0.10 | +33.3% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-0.12 | $-0.12 | 0.0% | = MET |
Q4 2021 | Nov 10, 2021 | $-0.11 | $-0.11 | 0.0% | = MET |
Q3 2021 | Aug 12, 2021 | $-0.11 | $-0.09 | +18.2% | ✓ BEAT |
Latest News
Nuvation Bio shares are trading higher after HC Wainwright maintained a Buy rating on the stock and raised its price target from $10 to $18.
📈 PositiveBenzinga•Dec 11, 2025, 05:22 PM
HC Wainwright & Co. Maintains Buy on Nuvation Bio, Raises Price Target to $18
📈 PositiveBenzinga•Dec 11, 2025, 11:22 AM
Nuvation Bio Announces Publication Of Results From Phase 2 Study Of Safusidenib In Patients With Chemotherapy- And Radiotherapy-Naïve Grade 2 IDH1-Mutant Gliomas
📈 PositiveBenzinga•Dec 3, 2025, 01:06 PM
HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $10 Price Target
📈 PositiveBenzinga•Dec 1, 2025, 11:40 AM
UPDATE: Nuvation Bio Discontinues Development Of NUV-1511; NUV-1511 Well Tolerated; Co Has Made This Decision Due To Lack Of Sufficiently Consistent Efficacy Across Cohorts; Continues Investment In IBTROZI Launch; Resources Budgeted For NUV-1511 To Be Transferred To Other Pipeline Molecules & To Development Of DDC Candidates
📉 NegativeBenzinga•Nov 26, 2025, 01:45 PM
Truist Securities Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $11
📈 PositiveBenzinga•Nov 24, 2025, 06:01 PM
Citizens Maintains Market Outperform on Nuvation Bio, Raises Price Target to $10
📈 PositiveBenzinga•Nov 20, 2025, 12:05 PM
Nuvation Bio rises as B. Riley starts at Buy on launch trajectory for lead drug
📈 PositiveSeeking Alpha•Nov 19, 2025, 07:17 PM
B. Riley Securities Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $12
📈 PositiveBenzinga•Nov 19, 2025, 12:15 PM•Also:
RBC Capital Maintains Outperform on Nuvation Bio, Raises Price Target to $8
📈 PositiveBenzinga•Nov 4, 2025, 04:33 PM
Citizens Maintains Market Outperform on Nuvation Bio, Raises Price Target to $8
📈 PositiveBenzinga•Nov 4, 2025, 12:56 PM
Nuvation Bio Q3 EPS $(0.16) Beats $(0.17) Estimate, Sales $13.120M Beat $6.614M Estimate
📈 PositiveBenzinga•Nov 3, 2025, 09:11 PM
Nuvation Bio Begins Late-Stage Study of New Brain Cancer Drug Safusidenib
📈 PositiveBenzinga•Oct 23, 2025, 11:33 AM
Wedbush Reiterates Outperform on Nuvation Bio, Maintains $6 Price Target
📈 PositiveBenzinga•Oct 13, 2025, 12:56 PM
Nuvation Bio up after enrollment update, Jefferies' bullish view
📈 PositiveSeeking Alpha•Sep 30, 2025, 03:30 PM•Also:
Nuvation Bio shares are trading higher after Jefferies initiated coverage with a Buy rating and a $10 price target. Additionally, the company enrolled its first patient in the Phase 3 TRUST-IV study of Ibtrozi for ROS1-positive early-stage NSCLC.
📈 PositiveBenzinga•Sep 30, 2025, 02:55 PM•Also:
Jefferies Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $10
📈 PositiveBenzinga•Sep 30, 2025, 11:37 AM•Also:
Nuvation Bio Enrolls First Patient In The TRUST-IV Phase 3 Study Of IBTROZI For Adjuvant Treatment Of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer
➖ NeutralBenzinga•Sep 30, 2025, 11:30 AM
HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $10 Price Target
📈 PositiveBenzinga•Sep 19, 2025, 11:36 AM
Nuvation Bio Says Japan's MHLW Approves IBTROZITM For Treatment Of Adult Patients With ROS1-Positive Unresectable, Advanced And/Or Recurrent NSCLC
📈 PositiveBenzinga•Sep 19, 2025, 11:32 AM
Frequently Asked Questions about NUVB
What is NUVB's current stock price?
Nuvation Bio Inc. (NUVB) is currently trading at $9.44 per share. The stock has moved +4.95% today.
What is the analyst price target for NUVB?
The average analyst price target for NUVB is $11.40, based on 1 analyst.
What sector is Nuvation Bio Inc. in?
Nuvation Bio Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NYSE exchange.
What is NUVB's market cap?
Nuvation Bio Inc. has a market capitalization of $3.23 billion, making it a mid-cap company.
Does NUVB pay dividends?
No, Nuvation Bio Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABCL
AbCellera Biologics Inc.
$3.60
Mkt Cap: $1.1B
AUPH
Aurinia Pharmaceuticals Inc.
$16.18
Mkt Cap: $2.1B
CLDX
Celldex Therapeutics, Inc.
$25.60
Mkt Cap: $1.7B
EWTX
Edgewise Therapeutics, Inc.
$25.55
Mkt Cap: $2.7B
GPCR
Structure Therapeutics Inc.
$64.94
Mkt Cap: $3.7B
JANX
Janux Therapeutics, Inc.
$13.79
Mkt Cap: $0.8B
OCUL
Ocular Therapeutix, Inc.
$12.56
Mkt Cap: $2.2B
QURE
uniQure N.V.
$23.99
Mkt Cap: $1.3B
VERA
Vera Therapeutics, Inc.
$51.22
Mkt Cap: $3.3B
VRDN
Viridian Therapeutics, Inc.
$31.92
Mkt Cap: $2.6B
Explore stocks similar to NUVB for comparison